GlassScriptPhysician profile
Ravisankar R Bolla
NPI 1730156993
$7,177.51
in general payments reported to CMS, 2019-2025
37 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $203 · 2021: $277 · 2022: $876 · 2023: $1,182 · 2024: $1,173 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,983.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,039.80 | 2019-2025 | Dragonfly Opstar, Pressurewire, Diamondback Coronary |
| Amgen INC. | $715.07 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $693.95 | 2019-2025 | |
| Boston Scientific Corporation | $603.90 | 2019-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $511.22 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $469.48 | 2019-2023 | |
| Novo Nordisk INC | $328.23 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abiomed | $322.08 | 2023-2025 | Impella |
| Janssen Pharmaceuticals, INC | $319.13 | 2019-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $262.04 | 2025 | Onpattro, Amvuttra |
| Merck Sharp & Dohme LLC | $258.19 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $207.01 | 2021-2025 | Farxiga, Wainua, Bevespi Aerosphere |
| Actelion Pharmaceuticals US, INC. | $163.52 | 2024-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.67 | 2019-2025 | Jardiance |
| Opsens INC. | $143.15 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravisankar Bolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.